CHICAGO, Nov. 30, 2015 (GLOBE NEWSWIRE) -- DECTRIS Ltd. has announced its Hybrid Photon Counting (HPC) technology based on the newest IBEX ASIC platform for X-ray medical imaging equipment. Hybrid Photon Counting technology is enabling original equipment manufacturers (OEMs) to transform X-ray medical imaging, from computerized tomography (CT) to digital breast mammography (DBT).
DECTRIS’ pioneering HPC detection technology, powered by the new IBEX ASIC platform, outperforms current technical standards — and delivers the best possible image quality based on single X-ray detection, highest sensitivity and lowest dose. Hybrid Photon Counting technology provides:
- Lowest possible dose — achieving the best signal-to-noise ratio via a noise-free detection with a high dynamic range and no dark current
- Radiation-hardness for ultimate long-term stability — via a specific design
- Very high frame rates — via dedicated ASIC and electronics
- Native spectral information for color X-ray imaging — via energy discrimination
- Almost perfect spatial resolution — via direct detection
Previously, X-ray detection in medical imaging has mainly relied on the indirect methods utilized by traditional integrating detectors lacking energy discrimination. Not only does the new IBEX ASIC sense every single photon in an X-ray, but it also provides the flexibility of two readout modes: A high resolution mode to detect subtle details and a spectral one to add color information to grey-scale radiology.
For OEMs, pairing Hybrid Photon Counting with advanced new X-ray medical imaging instruments and analysis algorithms, the additional spectral information will open up a new dimension in specificity.
DECTRIS is the world’s acknowledged leader in HPC detection, having produced more than 8,000 HPC detector modules to date — far more than any other source — for a variety of applications in science and industry.
As the leader, DECTRIS empowers medical imaging OEMs to shift the radiology into the era of native spectral X-ray imaging. The HPC proposition of geometrical accuracy, image quality, sensitivity at highest spectral fidelity will pave the way to precision medicine in a cost effective and safe way. Improved diagnostics (detection, characterization) based on existing contrast agents and new targeted biomarkers, will ultimately enable the logging of therapy responses.
For more information, visit DECTRIS Ltd. at RSNA 2015 in North Hall booth 6556. Or visit the DECTRIS website at http://medical.dectris.com or call +41.56.500.2180
About DECTRIS
As the technology leader in X-ray detection, DECTRIS aims to continuously improve measurement quality to enable new findings and innovative results in science, industry, and medicine. DECTRIS X-ray detectors make optimum use of the company’s pioneering Hybrid Photon Counting (HPC) technology. It has transformed basic research at synchrotron light sources, as well as in laboratory and industrial X-ray applications worldwide. For more information, visit http://medical.dectris.com or call +41.56.500.2180.
Note to Editors:
- Download high-resolution images for publication: https://flic.kr/s/aHsk6n7DsN
For further information please contact George Tudosie at [email protected]


Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 



